NEW YORK, Dec. 8, 2016 /PRNewswire/ -- Dr. Andre Goy, Chairman of the John Theurer Cancer Center and board member of Cota, the leading data and technology platform for value-based precision medicine, presented "Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma" on Sunday, December 4th at the 58th American Society of Hematology Annual Meeting & Exposition. The American Society of Hematology is the world's largest conference on blood disorders and took place December 3-6th.
Using real-world data organized by Cota, the study confirmed that the Mantle Cell Lymphoma International Prognostic Index (MIPI) score has prognostic value in separating patients with mantle cell lymphoma into cohorts with differing outcomes. The study also demonstrated that the Charlson Comorbidity Index (CCI), which categorizes patients by other medical conditions, has prognostic relevance.
"Most interestingly, for the first time our analysis was able to show the added benefit in combining the CCI comorbidity index with the currently used MIPI prognostic tool, allowing hematologists to tailor aggressiveness of therapy for mantle cell lymphoma patients," said Dr. Goy. "For example, we found that patients with low MIPI and high CCI can still benefit from tolerable standard dose approaches, while patients with high MIPI and high CCI cannot tolerate aggressive therapies and need investigational approaches from the beginning. Real-world data and better ways to stratify patients with mantle cell lymphoma are definitely critical to narrow the recognized outcome gap between patients on clinical trials and those treated outside trials."
All patient data for this study was sourced from Cota's database, and was analyzed using Cota's analysis and visualization platform. This study is part of an increasing volume of scientific contributions utilizing real-world evidence powered by Cota's data and technology.
Cota is a technology platform that enables providers, payers, and life science companies involved in diagnosing and treating complex diseases to optimize the care of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Address™ (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.
Cota's technology enriches raw medical records to create research-grade data, and joins it with a suite of analysis, visualization, and management tools. This enables providers, payers, and life sciences companies to analyze, report on, and research outcomes, costs, treatments, and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and science to help improve the lives of patients everywhere.
Media Contact: Matthew Levin, Email: email@example.com, Phone: +1 (646) 543-2682
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-andre-goy-and-cota-presented-impact-of-charlson-comorbidity-index-cci-and-refining-the-mipi-index-in-mantle-cell-lymphoma-at-the-58th-american-society-of-hematology-annual-meeting--exposition-300375673.html